Lanrektan

Tadalafil, the active ingredient in Lanrektan, is a phosphodiesterase type 5 (PDE5) inhibitor presented as a tablet for oral use. It treats erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension in adult males.

GNH USA supplies Lanrektan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lanrektan, a PDE5 inhibitor, is used in several conditions that involve smooth‑muscle relaxation.

- Erectile dysfunction: improves the ability to achieve and maintain an erection during sexual activity. - Benign prostatic hyperplasia: reduces urinary frequency, urgency and weak stream associated with prostate enlargement. - Pulmonary arterial hypertension: enhances exercise capacity and delays disease progression in patients with elevated pulmonary arterial pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often described as tension‑type. - Flushing: transient warmth and redness, typically on the face and neck. - Dyspepsia: occasional indigestion or upset stomach. - Nasal congestion: mild blockage or runny nose.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden vision loss: may indicate non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: unexplained decrease or loss of hearing. - Severe hypotension: marked drop in blood pressure, especially when combined with nitrates.

Before prescribing Lanrektan, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate history of heart disease, recent myocardial infarction or unstable angina. - Concomitant nitrate therapy: avoid due to risk of profound hypotension. - Renal or hepatic impairment: dose may need adjustment in moderate to severe dysfunction. - Visual disturbances: discontinue if sudden vision loss or visual field defects occur. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Tadalafil can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate): may cause severe hypotension. - Alpha‑blockers (e.g., doxazosin, prazosin): risk of additive blood‑pressure lowering effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, erythromycin): can increase tadalafil plasma concentrations. - CYP3A4 inducers (rifampin, carbamazepine): may reduce tadalafil effectiveness. - Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure for additive effects. - Alcohol: excessive intake may enhance hypotensive response.